Načítá se...
Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state
BCR-ABL1 kinase-induced chronic myeloid leukemia in chronic phase (CML-CP) usually responds to treatment with ABL tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib and nilotinib. In most patients TKIs reduce the leukemia cell load substantially, but some leukemia cells, for example leuke...
Uloženo v:
| Vydáno v: | Leuk Lymphoma |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4684553/ https://ncbi.nlm.nih.gov/pubmed/21299457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2010.546912 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|